Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)‐Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib
Abstract Tyrosine kinase inhibitors represented by sorafenib are the first‐line treatment for hepatocellular carcinoma (HCC), but the low response rate of HCC patient has become a clinical pain‐point. Emerging evidences have revealed that metabolic reprogramming plays an important role in regulating...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-07-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202207118 |